AstraZeneca (AZN) Share Forecast & Price Target

Compare

852 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AZN Analyst Ratings

Moderate Buy

12 Buy

2 Hold

1 Sell

Based on 15 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

14,624.11p

▲(4.26% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is 14,624.11p with a high forecast of 18,400.00p and a low forecast of 11,000.00p. The average price target represents a 4.26% change from the last price of 14,026.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10245":"10,245p","12284":"12,284p","14323":"14,323p","16362":"16,362p","18401":"18,401p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14624.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">15K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10245,12284,14323,16362,18401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13790,14144.615384615385,14499.23076923077,14853.846153846154,15208.461538461539,15563.076923076924,15917.692307692309,16272.307692307691,16626.923076923078,16981.53846153846,17336.153846153848,17690.76923076923,18045.384615384617,{"y":18400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13790,13854.162307692308,13918.324615384616,13982.486923076924,14046.649230769232,14110.81153846154,14174.973846153847,14239.136153846153,14303.298461538461,14367.460769230769,14431.623076923077,14495.785384615385,14559.947692307693,{"y":14624.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13790,13575.384615384615,13360.76923076923,13146.153846153846,12931.538461538461,12716.923076923076,12502.307692307691,12287.692307692309,12073.076923076924,11858.461538461539,11643.846153846154,11429.23076923077,11214.615384615385,{"y":11000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10246.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11103.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11884.96,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11287.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10534.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10500.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10329.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11026.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11850,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12436,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12470,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13836,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13790,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target18,400p

Average Price Target14,624p

Lowest Price Target11,000p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

10,500p→11,000p

Sell

-21.57%

Downside

Reiterated

01/16/26

Deutsche Bank Sticks to Their Sell Rating for AstraZeneca (AZN)

Matthew Weston

UBS

14,200p→16,300p

Buy

16.21%

Upside

Reiterated

01/15/26

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

16,000p

Buy

14.07%

Upside

Reiterated

01/15/26

J.P. Morgan Remains a Buy on AstraZeneca (AZN)

Shirley Chen

Barclays

12,283.34p

Buy

-12.42%

Downside

Reiterated

01/15/26

Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

14,500p

Buy

3.38%

Upside

Reiterated

01/07/26

Sachin Jain

Bank of America Securities

16,500p

Buy

17.64%

Upside

Reiterated

01/07/26

AstraZeneca: Broad Late-Stage Pipeline, Emerging Obesity Franchise, and Autoimmune CAR-T Platform Support Upside and Buy Rating

Justin Smith

Bernstein

18,400p

Buy

31.18%

Upside

Reiterated

12/04/25

Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)

Sarita Kapila

Morgan Stanley

14,000p→15,500p

Buy

10.51%

Upside

Reiterated

12/03/25

AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs

Seamus Fernandez

Guggenheim

14,200p→15,500p

Buy

10.51%

Upside

Reiterated

12/02/25

AstraZeneca (AZN) Receives a Rating Update from a Top Analyst

Unknown Analyst

HSBC

Not Ranked

HSBC

10,898.67p→12,283.34p

Buy

-12.42%

Downside

Reiterated

12/02/25

Michael Leuchten

Jefferies

15,000p

Buy

6.94%

Upside

Reiterated

12/01/25

AstraZeneca (AZN) Receives a Buy from Jefferies

Elmar Kraus

DZ BANK AG

Hold

―

Reiterated

11/10/25

AstraZeneca (AZN) Gets a Hold from DZ BANK AG

Rajan Sharma

Goldman Sachs

15,163p→15,504p

Buy

10.54%

Upside

Reiterated

11/07/25

AstraZeneca (AZN) Gets a Buy from Goldman Sachs

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

14,500p

Buy

3.38%

Upside

Reiterated

11/06/25

Shore Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

David Evans

Kepler Capital

11,300p

Hold

-19.44%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

10,500p→11,000p

Sell

-21.57%

Downside

Reiterated

01/16/26

Deutsche Bank Sticks to Their Sell Rating for AstraZeneca (AZN)

Matthew Weston

UBS

14,200p→16,300p

Buy

16.21%

Upside

Reiterated

01/15/26

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

16,000p

Buy

14.07%

Upside

Reiterated

01/15/26

J.P. Morgan Remains a Buy on AstraZeneca (AZN)

Shirley Chen

Barclays

12,283.34p

Buy

-12.42%

Downside

Reiterated

01/15/26

Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

14,500p

Buy

3.38%

Upside

Reiterated

01/07/26

Sachin Jain

Bank of America Securities

16,500p

Buy

17.64%

Upside

Reiterated

01/07/26

AstraZeneca: Broad Late-Stage Pipeline, Emerging Obesity Franchise, and Autoimmune CAR-T Platform Support Upside and Buy Rating

Justin Smith

Bernstein

18,400p

Buy

31.18%

Upside

Reiterated

12/04/25

Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)

Sarita Kapila

Morgan Stanley

14,000p→15,500p

Buy

10.51%

Upside

Reiterated

12/03/25

AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs

Seamus Fernandez

Guggenheim

14,200p→15,500p

Buy

10.51%

Upside

Reiterated

12/02/25

AstraZeneca (AZN) Receives a Rating Update from a Top Analyst

Unknown Analyst

HSBC

Not Ranked

HSBC

10,898.67p→12,283.34p

Buy

-12.42%

Downside

Reiterated

12/02/25

Michael Leuchten

Jefferies

15,000p

Buy

6.94%

Upside

Reiterated

12/01/25

AstraZeneca (AZN) Receives a Buy from Jefferies

Elmar Kraus

DZ BANK AG

Hold

―

Reiterated

11/10/25

AstraZeneca (AZN) Gets a Hold from DZ BANK AG

Rajan Sharma

Goldman Sachs

15,163p→15,504p

Buy

10.54%

Upside

Reiterated

11/07/25

AstraZeneca (AZN) Gets a Buy from Goldman Sachs

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

14,500p

Buy

3.38%

Upside

Reiterated

11/06/25

Shore Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

David Evans

Kepler Capital

11,300p

Hold

-19.44%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months

xxx

Success Rate

14/20 ratings generated profit

Average Return

+3.80%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +3.80% per trade.

1 Year

Matthew WestonUBS

Success Rate

34/36 ratings generated profit

Average Return

+17.86%

reiterated a buy rating 2 days ago

Copying Matthew Weston's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +17.86% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+25.18%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +25.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AZN has received 35 Buy Ratings, 2 Hold Ratings, and 4 Sell Ratings. AZN average Analyst price target in the past 3 months is 14,624.11.

Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is 1.58p with a range of 1.45p to 1.76p. The previous quarter’s EPS was 1.77p. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is 11.53B with a range of 11.18B to 12.07B. The previous quarter’s sales results were 11.27B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Stock Forecast FAQ

What is GB:AZN’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 14,624.11.

What is GB:AZN’s upside potential, based on the analysts’ average price target?

AstraZeneca PLC has 4.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AstraZeneca PLC a Buy, Sell or Hold?

AstraZeneca PLC has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 2 hold ratings and 1 sell ratings.

What is AstraZeneca PLC’s share price target?

The average share price target for AstraZeneca PLC is 14,624.11. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 18,400.00p ,and the lowest forecast is 11,000.00p. The average share price target represents 4.26% Increase from the current price of 14,026p.

What do analysts say about AstraZeneca PLC?

AstraZeneca PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of AstraZeneca PLC?

To buy shares of GB:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AstraZeneca (AZN) Share Forecast & Price Target

AZN Analyst Ratings

AZN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

AZN Analyst Recommendation Trends

AZN Financial Forecast

AZN Earnings Forecast

AZN Sales Forecast

AZN Stock Forecast FAQ

Detailed List of Analyst Forecasts